Table 1.
Clinical and biological features and corresponding VMAT1 and VMAT2 expression in patients with high-risk neuroblastoma.
| Characteristic | Overall N (%) | Median VMAT1 Composite Scorea | p-value | Median VMAT2 Composite Scorea | p-value |
|---|---|---|---|---|---|
| Age ≥ 18 months | 66 (86.8) | 60 | 0.15 | 203 | 0.08 |
| Age < 18 months | 10 (13.2) | 0 | 10 | ||
| MYCN Amplified | 28 (41.8) | 0 | 0.003 | 5 | < 0.001 |
| MYCN Non-Amplified | 39 (58.2) | 90 | 270 | ||
| Adrenal Primary | 43 (56.6) | 54 | 0.56 | 210 | 0.07 |
| Non-Adrenal Primary | 33 (43.4) | 38 | 102 | ||
| Catecholamine Positive | 61 (83.6) | 60 | 0.12 | 195 | 0.11 |
| Catecholamine Negative | 12 (16.4) | 0 | 2 | ||
| Unfavorable Histology | 71 (95.9) | 54 | 0.82 | 153 | 0.19 |
| Favorable Histology | 3 (4.1) | 83 | 297 | ||
| Un/Poorly Differentiated | 59 (89.4) | 35 | 0.48 | 153 | 0.74 |
| Differentiating | 7 (10.6) | 79 | 195 | ||
| High MKI | 24 (36.4) | 0 | 0.03 | 0 | < 0.001 |
| Low/Intermediate MKI | 42 (63.6) | 60 | 248 | ||
| Hypodiploid/Diploid | 39 (57.4) | 10 | 0.07 | 30 | 0.009 |
| Hyperdiploid | 29 (42.6) | 74 | 240 | ||
| 11q Aberration | 6 (42.9) | 140 | 0.10 | 293 | 0.02 |
| No 11q Aberration | 8 (57.1) | 23 | 70 | ||
| 1p LOH | 5 (33.3) | 0 | 0.35 | 0 | 0.14 |
| No 1p LOH | 10 (66.6) | 85 | 263 | ||
a
Composite score is product of intensity score and percent tumor cells positive. VMAT1 data for 74 patients. VMAT2 data for 76 patients.